Sinovac is a leading vaccine player in China with a proven track record in product development and commercialization.  As of October 2009, the Company has five (including H1N1) marketed products and a robust pipeline of products under development.  Sinovac is focused on providing Chinese citizens with affordable, international quality vaccines along with pursuing opportunities to provide its vaccines to people worldwide. Importantly, Sinovac has the fully integrated human vaccine development expertise and manufacturing capability necessary to support the pipeline of potential new vaccines. 

 

Sinovac will continue to research and develop innovative vaccines to create competitive advantages and further enhance profit margins.  The Company intends to invest approximately 5-10% of revenues in research and development, with the goal of having one to two vaccine candidates entering clinical trials each year and reaching commercialization in the subsequent years.  In addition to human vaccines, Sinovac has expanded its development to include animal use vaccines.

 

Sinovac has a well-established sales, marketing and distribution network in China, covering virtually the entire domestic market, excluding Tibet.  Sinovac is also very focused on expanding its global reach through strategic collaborations.